CAS NO: | 38609-97-1 |
包装 | 价格(元) |
Free Sample (0.1-0.5mg) | 电议 |
10mM (in 1mL DMSO) | 电议 |
5mg | 电议 |
10mg | 电议 |
50mg | 电议 |
100mg | 电议 |
200mg | 电议 |
500mg | 电议 |
Cas No. | 38609-97-1 |
别名 | 吖啶酮乙酸 |
Canonical SMILES | O=C(O)CN(C1=C2C=CC=C1)C3=CC=CC=C3C2=O |
分子式 | C15H11NO3 |
分子量 | 253.26 |
溶解度 | DMSO: 125 mg/mL (493.56 mM); Water:< 0.1 mg/mL (insoluble) |
储存条件 | Store at -20°C |
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while. |
Shipping Condition | Evaluation sample solution : ship with blue ice All other available size: ship with RT , or blue ice upon request |
产品描述 | Cridanimod is a small-molecule immunomodulator and interferon inducer[1]. Cridanimod is a potent progesterone receptor (PR) activator mediated through induction of IFNα and IFNβ expression[2]. Cridanimod (IM; 1-6 mg; twice a week) has a significantly longer survival time. Cridanimod significant increases in IFNα and -β in cridanimod-treated mice in a dose-dependent manner[1]. Animal Model: Athymic mice with hec50co cells[1] [1]. Xenetic Biosciences Announces FDA Acceptance of Investigational New Drug Application to Initiate Phase 2 Clinical Trial of Virexxa® in Endometrial Cancer. AUGUST 19, 2016 [2]. Matthew J. Carlson, et al. Cridanimod and progestin therapy in hormone-resistant endometrial cancer. Journal of Clinical Oncology, January 30, 2017. |